2.8677
전일 마감가:
$2.845
열려 있는:
$2.78
하루 거래량:
207.33K
Relative Volume:
0.08
시가총액:
$490.35M
수익:
$25.55M
순이익/손실:
$-341.97M
주가수익비율:
-1.0242
EPS:
-2.8
순현금흐름:
$-304.44M
1주 성능:
+2.18%
1개월 성능:
-7.68%
6개월 성능:
-39.55%
1년 성능:
-58.87%
릴레이 테라퓨틱스 Stock (RLAY) Company Profile
명칭
Relay Therapeutics Inc
전화
617-370-8837
주소
399 BINNEY STREET, CAMBRIDGE
RLAY을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
RLAY
Relay Therapeutics Inc
|
2.86 | 478.33M | 25.55M | -341.97M | -304.44M | -2.80 |
![]()
ONC
Beigene Ltd Adr
|
240.88 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
432.88 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.33 | 42.47M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
585.19 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
73.16 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
릴레이 테라퓨틱스 Stock (RLAY) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-04-17 | 개시 | Wells Fargo | Equal Weight |
2024-09-10 | 재개 | Goldman | Buy |
2024-09-10 | 업그레이드 | Jefferies | Hold → Buy |
2024-09-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2024-05-10 | 업그레이드 | Barclays | Equal Weight → Overweight |
2023-04-20 | 업그레이드 | Jefferies | Underperform → Hold |
2023-04-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
2023-04-13 | 개시 | Raymond James | Outperform |
2023-02-03 | 개시 | Oppenheimer | Outperform |
2022-09-30 | 개시 | Barclays | Equal Weight |
2022-09-02 | 개시 | Stifel | Buy |
2022-06-06 | 개시 | Jefferies | Underperform |
2022-02-01 | 개시 | Berenberg | Buy |
2021-07-21 | 개시 | BofA Securities | Buy |
2020-12-15 | 재확인 | H.C. Wainwright | Buy |
2020-12-08 | 개시 | JMP Securities | Mkt Outperform |
2020-11-05 | 개시 | H.C. Wainwright | Buy |
2020-08-10 | 개시 | Cowen | Outperform |
2020-08-10 | 개시 | Goldman | Buy |
2020-08-10 | 개시 | Guggenheim | Buy |
2020-08-10 | 개시 | JP Morgan | Neutral |
모두보기
릴레이 테라퓨틱스 주식(RLAY)의 최신 뉴스
Northern Trust Corp Buys 231,713 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
BNP Paribas Financial Markets Invests $987,000 in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Stifel Financial Corp Makes New Investment in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Transcript : Relay Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 03 - marketscreener.com
Relay Therapeutics, Inc. (RLAY): One of the Best Low Priced Biotech Stocks to Buy Now - Yahoo Finance
10 Best Low-Priced Biotech Stocks to Buy Now - Insider Monkey
HC Wainwright Issues Optimistic Forecast for RLAY Earnings - Defense World
Relay Therapeutics, Inc. (RLAY): A Bull Case Theory - MSN
89,949 Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY) Purchased by First Trust Advisors LP - Defense World
Dimensional Fund Advisors LP Grows Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Q2 EPS Estimate for Relay Therapeutics Lowered by Analyst - Defense World
Relay Therapeutics to Participate in Two Upcoming Investor Conferences - The Manila Times
Hsbc Holdings PLC Has $458,000 Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - The AM Reporter
MetLife Investment Management LLC Grows Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Guggenheim Lowers Price Target for Relay Therapeutics (RLAY) to $10.00 | RLAY Stock News - GuruFocus
Relay Therapeutics (RLAY) Stock Target Reduced Amid Strategic Changes and Progress | RLAY Stock News - GuruFocus
Marshall Wace LLP Lowers Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Raymond James Financial Inc. Takes $779,000 Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Wells Fargo & Company MN Decreases Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics Inc (RLAY) Q1 2025 Earnings: EPS Loss of $0.4 - GuruFocus
Relay Therapeutics (RLAY) Reports Decline in Q1 Revenue | RLAY S - GuruFocus
Relay Therapeutics Extends Cash Runway and Advances Clinical Trials - TipRanks
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates | RLAY Stock News - GuruFocus
Relay Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Relay Therapeutics, Inc. SEC 10-Q Report - TradingView
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates - The Manila Times
Relay Therapeutics Extends Cash Runway into 2029 Amid Clinical Trial Advancements - Nasdaq
Barclays PLC Has $1.29 Million Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Invesco Ltd. Acquires 5,261 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
There Is A Lot Of Upside Potential For Relay Therapeutics Inc(NASDAQ: RLAY) - Stocksregister
why Relay Therapeutics Inc [RLAY] is a Good Choice for Investors After New Price Target of $17.40 - dbtnews.com
Relay Therapeutics executive sells $36,540 in stock By Investing.com - Investing.com Nigeria
Relay Therapeutics executive sells $36,540 in stock - Investing.com Australia
LPL Financial LLC Sells 6,564 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics president sells $95,381 in stock By Investing.com - Investing.com South Africa
Relay Therapeutics chief legal officer sells $44,040 in stock By Investing.com - Investing.com South Africa
Relay Therapeutics CFO sells shares worth $44,246 By Investing.com - Investing.com South Africa
Relay Therapeutics Inc Stock: Executives Sell Shares Amid Mixed Signals - sharewise
Relay Therapeutics president sells $95,381 in stock - Investing.com Australia
Relay Therapeutics CFO sells shares worth $44,246 - Investing.com Australia
Relay Therapeutics chief legal officer sells $44,040 in stock - Investing.com
Relay Therapeutics Executives Sell Shares to Cover Tax Obligations and Under Trading Plan - TradingView
Healthy Upside Potential: Relay Therapeutics Inc (RLAY) - Sete News
Trading Day Review: Relay Therapeutics Inc (RLAY) Loses Momentum, Closing at 3.10 - DWinneX
릴레이 테라퓨틱스 (RLAY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
릴레이 테라퓨틱스 주식 (RLAY) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Rahmer Peter | See remarks |
Apr 28 '25 |
Sale |
3.17 |
1,364 |
4,324 |
400,820 |
Catinazzo Thomas | Chief Financial Officer |
Apr 30 '25 |
Sale |
3.00 |
12,943 |
38,829 |
355,376 |
Catinazzo Thomas | Chief Financial Officer |
Apr 29 '25 |
Sale |
3.23 |
3,558 |
11,492 |
368,319 |
Catinazzo Thomas | Chief Financial Officer |
Apr 28 '25 |
Sale |
3.17 |
2,690 |
8,527 |
371,877 |
Bergstrom Donald A | President, R&D |
Apr 30 '25 |
Sale |
3.00 |
27,472 |
82,416 |
583,490 |
Bergstrom Donald A | President, R&D |
Apr 28 '25 |
Sale |
3.17 |
4,090 |
12,965 |
610,962 |
Adams Brian | Chief Legal Officer |
Apr 30 '25 |
Sale |
3.00 |
12,943 |
38,829 |
391,385 |
Adams Brian | Chief Legal Officer |
Apr 28 '25 |
Sale |
3.17 |
1,644 |
5,211 |
404,328 |
자본화:
|
볼륨(24시간):